Safety and efficacy of maintenance therapy (MT) with a nonspecific cytochrome-P 17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castratation-resistant prostate cancer (mCRPC) patients.
Ignacio Gil-Bazo
No relevant relationships to disclose
Ainhoa Castillo
No relevant relationships to disclose
Maria E. Zudaire
No relevant relationships to disclose
Estefania Arevalo
No relevant relationships to disclose
Omar Esteban Carranza
No relevant relationships to disclose
Juan Pablo Fusco
No relevant relationships to disclose
Eduardo Castanon
No relevant relationships to disclose
Jose Luis Perez-Gracia
No relevant relationships to disclose
José María López-Picazo
No relevant relationships to disclose
Alfonso Gurpide
No relevant relationships to disclose
Jesus Garcia-Foncillas
No relevant relationships to disclose